Dicerna Pharmaceuticals Inc Uncategorized Contracts & Agreements
15 Contracts & Agreements
- Royalty Acquisition Agreement by and between the Company and Royalty Pharma PLC, dated as of April 8, 2021 (Filed With SEC on May 6, 2021)
- Patent Cross-License Agreement by and between the Company and Alnylam Pharmaceuticals, Inc., dated as of April 3, 2020 (Filed With SEC on August 6, 2020)
- Description of Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934, as amended (Filed With SEC on February 28, 2020)
- Additional Target Agreement, dated December 31, 2018, by and between the Company and Boehringer Ingelheim International GmbH (Filed With SEC on March 13, 2019)
- [Remainder of Page Intentionally Left Blank] -2- (Filed With SEC on March 30, 2017)
- See Restrictive Legends on Reverse Side of Certificate Incorporated Under the Laws of the State of Delaware (Filed With SEC on March 30, 2017)
- DICERNA PHARMACEUTICALS, INC. 2016 INDUCEMENT PLAN (Filed With SEC on March 10, 2016)
- ******* (Filed With SEC on March 10, 2016)
- LICENSEAGREEMENT by and between DICERNA PHARMACEUTICALS, INC., on the one hand, and PROTIVA BIOTHERAPEUTICS INC. and TEKMIRA PHARMACEUTICALS CORPORATION on the other hand... (Filed With SEC on March 12, 2015)
- [Company Letterhead] (Filed With SEC on January 28, 2014)
- COMMERCIAL LICENCE AGREEMENT (Filed With SEC on January 28, 2014)
- COMMERCIAL LICENCE AGREEMENT (Filed With SEC on December 31, 2013)
- DICERNA PHARMACEUTICALS, INC. 480 Arsenal Street Building 1, Suite 120 Watertown, MA 02472 February 28, 2011 (Filed With SEC on December 31, 2013)
- DICERNA PHARMACEUTICALS, INC. 480 Arsenal Street Building 1, Suite 120 Watertown, MA 02472 (Filed With SEC on December 31, 2013)
- EMPLOYMENTAGREEMENT (Filed With SEC on December 31, 2013)
